Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Neurocrine Bioscienc (NBIX)

Neurocrine Bioscienc (NBIX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,142,686
  • Shares Outstanding, K 96,134
  • Annual Sales, $ 1,134 M
  • Annual Income, $ 89,600 K
  • 60-Month Beta 0.53
  • Price/Sales 10.78
  • Price/Cash Flow 102.32
  • Price/Book 7.91
Trade NBIX with:

Options Overview Details

View History
  • Implied Volatility 35.23% ( -1.81%)
  • Historical Volatility 31.04%
  • IV Percentile 10%
  • IV Rank 21.02%
  • IV High 63.50% on 01/26/22
  • IV Low 27.71% on 08/18/22
  • Put/Call Vol Ratio 0.03
  • Today's Volume 35
  • Volume Avg (30-Day) 213
  • Put/Call OI Ratio 0.53
  • Today's Open Interest 9,124
  • Open Int (30-Day) 9,909

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate 1.26
  • Number of Estimates 11
  • High Estimate 2.45
  • Low Estimate 0.93
  • Prior Year -0.08
  • Growth Rate Est. (year over year) +1,675.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
111.25 +13.99%
on 11/17/22
129.29 -1.92%
on 12/01/22
+4.75 (+3.89%)
since 11/02/22
3-Month
100.04 +26.76%
on 09/28/22
129.29 -1.92%
on 12/01/22
+23.80 (+23.10%)
since 09/02/22
52-Week
71.88 +76.43%
on 01/10/22
129.29 -1.92%
on 12/01/22
+46.17 (+57.25%)
since 12/02/21

Most Recent Stories

More News
Neurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediatric Patients with SCN8A-Related Epilepsies at AES 2022

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today reported demographic and clinical...

NBIX : 126.81 (+0.40%)
Could Pfizer Stock Help You Retire a Millionaire?

Leading biopharmaceutical company Pfizer’s (PFE) third-quarter results demonstrated strength across most areas of its business. Moreover, the company raised its 2022 financial guidance for revenues and...

NBIX : 126.81 (+0.40%)
NVO : 126.90 (+0.61%)
PFE : 50.91 (-0.33%)
RHHBY : 41.0800 (-0.15%)
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?

Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.

NBIX : 126.81 (+0.40%)
MDY : 470.10 (+0.10%)
CPRX : 17.27 (+3.85%)
AVEO : 14.92 (-0.07%)
IMCR : 60.58 (+1.00%)
AMGN : 285.51 (-0.15%)
VRTX : 321.37 (+0.19%)
REGN : 766.39 (+0.68%)
GILD : 89.03 (+1.29%)
1 Warren Buffett Stock That Should Be on Your Buy List This Fall

Investors can take a cue from Warren Buffet’s portfolio and consider buying the popular healthcare name Johnson & Johnson (JNJ), as it is expected to weather any possible economic conditions in the upcoming...

JNJ : 178.88 (+0.08%)
NBIX : 126.81 (+0.40%)
NVO : 126.90 (+0.61%)
RHHBY : 41.0800 (-0.15%)
1 Stock to Buy Today and Thank Yourself Later For

Global biopharmaceutical company Bristol-Myers Squibb (BMY) reported solid third-quarter financials and is well-positioned to witness immense growth in the upcoming quarters, driven by continued progress...

BMY : 81.13 (+0.31%)
NBIX : 126.81 (+0.40%)
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor...

NBIX : 126.81 (+0.40%)
3 Reasons Growth Investors Will Love Neurocrine (NBIX)

Neurocrine (NBIX) could produce exceptional returns because of its solid growth attributes.

NBIX : 126.81 (+0.40%)
Ironwood's (IRWD) Q3 Earnings Beat, Linzess Volume Grows

Ironwood (IRWD) beat earnings estimates in the third quarter. Sales, though missing estimates, rose year over year. Stock up.

AZN : 68.47 (+0.19%)
IRWD : 12.26 (+2.51%)
NBIX : 126.81 (+0.40%)
ABBV : 163.66 (+1.26%)
Zoetis' (ZTS) Lags Q3 Earnings Estimates, Lowers 2022 Guidance

Zoetis' (ZTS) earnings miss estimates in third-quarter 2022. Revenues, though up, also miss estimates due to the supply constraints in the international market. Zoetis lowers its financial guidance.

NBIX : 126.81 (+0.40%)
ZTS : 157.42 (+0.50%)
AERI : 15.25 (+0.07%)
ASRT : 3.06 (+2.00%)
Is Kura Oncology (KURA) Outperforming Other Medical Stocks This Year?

Here is how Kura Oncology (KURA) and Neurocrine Biosciences (NBIX) have performed compared to their sector so far this year.

KURA : 16.00 (+2.76%)
NBIX : 126.81 (+0.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding...

See More

Key Turning Points

3rd Resistance Point 133.25
2nd Resistance Point 130.34
1st Resistance Point 128.58
Last Price 126.81
1st Support Level 123.91
2nd Support Level 121.00
3rd Support Level 119.24

See More

52-Week High 129.29
Last Price 126.81
Fibonacci 61.8% 107.36
Fibonacci 50% 100.58
Fibonacci 38.2% 93.81
52-Week Low 71.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar